The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) announced yesterday that it will not make any sudden changes to the nation’s regulatory framework following the country’s exit from the European Union.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) announced yesterday that it will not make any sudden changes to the nation’s regulatory framework following the country’s exit from the European Union.
In an update to pharmaceutical companies on preparations for the so-called Brexit, MHRA reassured industry that “goods placed on the market under Union law before the withdrawal date may freely circulate on the markets of the [United Kingdom] and the [European Union] with no need for product modifications or re-labelling; be put into service where provided in Union law, and that the goods concerned should be subject to continued oversight.”
MHRA also notes that it is seeking to negotiate an “implementation period” that would allow the United Kingdom and the European Union to allow access to “…one another’s markets to continue on current terms throughout this period, and for it to be based on the existing structure of EU rules and regulations” during the transition, as well as a “close working relationship” with EU regulators after the transition is complete.
However, the agency acknowledged the fact that it is possible that no agreement will be reached to allow the United Kingdom to have a continued relationship with the European Medicines Agency (EMA). In the event of such a “no-deal” outcome, the MHRA plans to convert the existing EU legislative framework into UK law at the time of exit so that there will be no sudden changes to UK regulation. Yet changes will follow, suggests MHRA, saying that its “pragmatic” adjustments to regulatory requirements would be rolled out with adequate notice to ensure that companies have enough time to implement the changes.
The Association of the British Pharmaceutical Industry (ABPI) responded to the MHRA update by noting that it shares the government’s hope for a strong working relationship with the EMA post-Brexit, but noted that industry needs more detail about MHRA’s plans for a no-deal scenario.
“For patients and the public there are very real consequences of failing to get this right, and we will continue to work with our members, regulators, governments and the [European Commission] to mitigate these risks. The complex issues surrounding medicines regulation and supply chain need to be front and [center] in the second phase of talks,” wrote ABPI in a statement.
The UK Bioindustry Association (BIA) also voiced its hopes for a continued partnership with the EMA; the organization’s head of regulatory affairs, Christiane Abouzeid, PhD, said in a statement, “The BIA has long advocated for retaining ongoing UK regulatory cooperation with the European Union on medicines to ensure minimal disruption to patient access in both the [United Kingdom] and [European Union].”
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.